Literature DB >> 31550216

Ethyl Acetohydroxamate Incorporated Chalcones: Unveiling a Novel Class of Chalcones for Multitarget Monoamine Oxidase-B Inhibitors Against Alzheimer's Disease.

Seung Cheol Baek1, Jae Pil Lee1, T M Rangarajan2, Rishi Pal Singh2, Manjula Singh3, Giuseppe Felice Mangiatordi4, Orazio Nicolotti5, Hoon Kim1, Bijo Mathew6.   

Abstract

BACKGROUND: Chalcones are considered as the selective scaffold for the inhibition of MAO-B.
OBJECTIVES: A previously synthesized ethyl acetohydroxamate-chalcones (L1-L22) were studied for their inhibitory activities against human recombinant monoamine oxidase A and B (hMAO-A and hMAO-B, respectively) and acetylcholinesterase (AChE) as multi-target directed ligands for the treatment of Alzheimer's Disease (AD).
METHODS: Enzyme inhibition studies of MAO-A, MAO-B and AChE is carried out. Computational studies such as Molecular docking, Molecular Mechanics/Generalized Born Surface Area calculations, ADMET prediction, and protein target prediction are also performed.
RESULTS: Among the screened compounds, compound L3 has most potent hMAO-B inhibition with an IC50 value of 0.028 ± 0.0016 µM, and other compounds, L1, L2, L4, L8, L12, and L21 showed significant potent hMAO-B inhibition with IC50 values of 0.051 ± 0.0014, 0.086 ± 0.0035, 0.036 ± 0.0011, 0.096 ± 0.0061, 0.083 ± 0.0016, and 0.038 ± 0.0021 µM, respectively. On the other hand, among the tested compounds, compound L13 showed highest hMAO-A inhibition with an IC50 value of 0.51± 0.051 µM and L9 has a significant value of 1.85 ± 0.045 µM. However, the compounds L3 and L4 only showed high selectivities for hMAO-B with Selectivity Index (SI) values of 621.4 and 416.7, respectively. Among the substituents in ring A of ethyl acetohydroxamate-chalcones (L1-L9), F atom at p-position (L3) showed highest inhibitory effect against hMAO-B. This result supports the uniqness and bizarre behavior of fluorine. Moreover, chalcones L3, L4, L9, L11, and L12 showed potential AChE inhibitory effect with IC50 values of 0.67, 0.85, 0.39, 0.30, and 0.45 µM, respectively. Inhibitions of hMAO-B by L3 or L4 were recovered to the level of the reversible reference (lazabemide), and were competitive with Ki values of 0.0030 ± 0.0002 and 0.0046 ± 0.0005 µM, respectively. Inhibitions of AChE by L3 and L11 were of the competitive and mixed types with Ki values of 0.30 ± 0.044 and 0.14 ± 0.0054 µM, respectively.
CONCLUSION: The studies indicated that L3 and L4 are considered to be promising multitarget drug molecules with potent, selective, and reversible competitive inhibitors of hMAO-B and with highly potent AChE inhibitory effect. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.

Entities:  

Keywords:  AChE; Alzheimer's disease; ethyl acetohydroxamate-chalcones; hMAOs; molecular docking; selective competitive and reversiblezzm321990inhibitor.

Year:  2019        PMID: 31550216     DOI: 10.2174/1871527318666190906101326

Source DB:  PubMed          Journal:  CNS Neurol Disord Drug Targets        ISSN: 1871-5273            Impact factor:   4.388


  6 in total

1.  Novel Class of Chalcone Oxime Ethers as Potent Monoamine Oxidase-B and Acetylcholinesterase Inhibitors.

Authors:  Jong Min Oh; T M Rangarajan; Reeta Chaudhary; Rishi Pal Singh; Manjula Singh; Raj Pal Singh; Anna Rita Tondo; Nicola Gambacorta; Orazio Nicolotti; Bijo Mathew; Hoon Kim
Journal:  Molecules       Date:  2020-05-18       Impact factor: 4.411

2.  Morpholine-based chalcones as dual-acting monoamine oxidase-B and acetylcholinesterase inhibitors: synthesis and biochemical investigations.

Authors:  Rani Sasidharan; Bo Hyun Eom; Jeong Hyun Heo; Jong Eun Park; Mohamed A Abdelgawad; Arafa Musa; Nicola Gambacorta; Orazio Nicolotti; Sreedharannair Leelabaiamma Manju; Bijo Mathew; Hoon Kim
Journal:  J Enzyme Inhib Med Chem       Date:  2021-12       Impact factor: 5.051

3.  Acetylcholinesterase and butyrylcholinesterase inhibitory activities of khellactone coumarin derivatives isolated from Peucedanum japonicum Thurnberg.

Authors:  Jeong Hyun Heo; Bo Hyun Eom; Hyung Won Ryu; Myung-Gyun Kang; Jong Eun Park; Doo-Young Kim; Jung-Hee Kim; Daeui Park; Sei-Ryang Oh; Hoon Kim
Journal:  Sci Rep       Date:  2020-12-10       Impact factor: 4.379

4.  Trimethoxylated Halogenated Chalcones as Dual Inhibitors of MAO-B and BACE-1 for the Treatment of Neurodegenerative Disorders.

Authors:  Payyalot Koyiparambath Vishal; Jong Min Oh; Ahmed Khames; Mohamed A Abdelgawad; Aathira Sujathan Nair; Lekshmi R Nath; Nicola Gambacorta; Fulvio Ciriaco; Orazio Nicolotti; Hoon Kim; Bijo Mathew
Journal:  Pharmaceutics       Date:  2021-06-08       Impact factor: 6.321

Review 5.  Exploration of chalcones and related heterocycle compounds as ligands of adenosine receptors: therapeutics development.

Authors:  Chrisna Matthee; Gisella Terre'Blanche; Lesetja J Legoabe; Helena D Janse van Rensburg
Journal:  Mol Divers       Date:  2021-06-27       Impact factor: 3.364

6.  Design, Synthesis, and Biological Evaluation of Pyridazinones Containing the (2-Fluorophenyl) Piperazine Moiety as Selective MAO-B Inhibitors.

Authors:  Muhammed Çeçen; Jong Min Oh; Zeynep Özdemir; Saliha Ebru Büyüktuncel; Mehtap Uysal; Mohamed A Abdelgawad; Arafa Musa; Nicola Gambacorta; Orazio Nicolotti; Bijo Mathew; Hoon Kim
Journal:  Molecules       Date:  2020-11-17       Impact factor: 4.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.